

12 Sep 2023 | News

# Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna's progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim's head of innovation on R&D priorities.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 8 September 2023, including: the rise of [Novo Nordisk A/S](#); senior level changes at [Novartis AG](#); [Moderna, Inc.](#)'s progress against BA.2.86; major new CNS drugs coming; and [Boehringer Ingelheim GmbH](#)'s head of innovation on R&D priorities.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Now Europe's Most Valuable Company, Can Novo Nordisk Live Up To Investor Expectations?](#)" - Scrip, 6 Sep, 2023.)

(Also see "[Novartis Appoints AbbVie Immunology Leader Horber To Succeed Tschudin](#)" - Scrip, 6 Sep, 2023.)

(Also see "[Moderna COVID-19 Vaccine First Past The Post With Clinical Data For BA.2.86](#)" - Scrip, 6 Sep, 2023.)

(Also see "[\*Schizophrenia, Depression And Neuropathy: What's Coming In 2024\*](#)" - Scrip, 8 Sep, 2023.)

(Also see "[\*Boehringer's Innovation Strategy Does Not Avoid Areas With Heavy Competition\*](#)" - Scrip, 4 Sep, 2023.)

[Click here to explore this interactive content online](#) ✎